Everest Medicines Expands Strategic Investment in I-MAB

Everest will invest US $30.9 million (equivalent to approximately HK$ 242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.- I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers.- I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complem ...